Home » Stocks » MTEM

Molecular Templates, Inc. (MTEM)

Stock Price: $8.63 USD -0.30 (-3.36%)
Updated Jun 15, 2021 4:00 PM EDT - Market closed
Market Cap 497.56M
Revenue (ttm) 17.92M
Net Income (ttm) -109.68M
Shares Out 52.56M
EPS (ttm) -2.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 15
Last Price $8.63
Previous Close $8.93
Change ($) -0.30
Change (%) -3.36%
Day's Open 8.99
Day's Range 8.47 - 9.04
Day's Volume 463,357
52-Week Range 7.51 - 16.41

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -282.14% and -89.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and develo...

1 month ago - GlobeNewsWire

Posters will feature data on MT-5111 (targeting HER2), MT-6402 (targeting PD-L1) and a novel CTLA-4-targeted ETB Posters will feature data on MT-5111 (targeting HER2), MT-6402 (targeting PD-L1) and a no...

2 months ago - GlobeNewsWire

The company is taking back rights to one drug candidate and discontinuing development of another.

Other stocks mentioned: TAK
2 months ago - The Motley Fool

Molecular Templates Inc (NASDAQ: MTEM) has decided to discontinue the development of MT-3724, its only first-generation engineered toxin bodies (ETB), and focus its resources on the development of next-...

2 months ago - Benzinga

Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma

2 months ago - GlobeNewsWire

AUSTIN, Texas, March 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and deve...

2 months ago - GlobeNewsWire

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases this week.

Other stocks mentioned: ADC, CAR, ZTS, AAT, INCY, OPK, RPRX ...
3 months ago - Benzinga

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

Other stocks mentioned: BMBL, FISV, ATEX, CRVS, DBTX, NEXI, ONCR ...
3 months ago - Benzinga

Community Health Systems (NYSE: CYH) shares are trading higher after the company reported better-than-expected fourth-quarter sales results. Community Health Systems is the largest publicly owned hospit...

Other stocks mentioned: NVTA, VERU, CYH
3 months ago - Benzinga

AUSTIN, Texas, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and developm...

3 months ago - GlobeNewsWire

Molecular Templates to receive $70 million upfront payment with potential for additional milestone and royalty payments on future sales Molecular Templates to receive $70 million upfront payment with po...

4 months ago - GlobeNewsWire

Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to Begin ...

5 months ago - GlobeNewsWire

AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and develo...

6 months ago - GlobeNewsWire

AUSTIN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the disco...

7 months ago - GlobeNewsWire

AUSTIN, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

9 months ago - GlobeNewsWire

AUSTIN, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the dis...

10 months ago - GlobeNewsWire

AUSTIN, Texas, July 20, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the dis...

10 months ago - GlobeNewsWire

Update Provided Phase I Study of MT-5111 in HER2-positive Cancers

11 months ago - GlobeNewsWire

Molecular Templates: Updates To Thesis, Pursuing Validated Targets With Unique MOA

1 year ago - Seeking Alpha

AUSTIN, Texas, May 22, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the disc...

1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor Molecular Templates

1 year ago - Zacks Investment Research

Take advantage of panic selling with these 7 cheap stocks.

Other stocks mentioned: APAM, BCRX, CALX, OESX, SPN, TRN
1 year ago - Zacks Investment Research

Milestone Triggers $10 Million Payment to Molecular Templates Milestone Triggers $10 Million Payment to Molecular Templates

1 year ago - GlobeNewsWire

Three Products Advancing in the Clinic with Additional Pipeline Growth to Come from Internal Research and Partnerships Three Products Advancing in the Clinic with Additional Pipeline Growth to Come from...

1 year ago - GlobeNewsWire

AUSTIN, Texas, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s proprie...

1 year ago - GlobeNewsWire

New drugs from these companies seek to enable more patients to receive cutting-edge cell and gene therapies.

Other stocks mentioned: MGTA
1 year ago - The Motley Fool

AUSTIN, Texas, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and develo...

1 year ago - GlobeNewsWire

AUSTIN, Texas, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and develo...

1 year ago - GlobeNewsWire

AUSTIN, Texas, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s propriet...

1 year ago - GlobeNewsWire

Shares have risen by 20% since my initial article.

1 year ago - Seeking Alpha

AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprie...

1 year ago - GlobeNewsWire

Molecular Templates (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Shares have risen as a result of optimism regarding Takeda partnership and advancing ETB pipeline.

2 years ago - Seeking Alpha

As of late, it has definitely been a great time to be an investor Molecular Templates.

2 years ago - Zacks Investment Research

Molecular Templates (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

About MTEM

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TA... [Read more...]

Industry
Biotechnology
CEO
Eric Poma
Employees
247
Stock Exchange
NASDAQ
Ticker Symbol
MTEM
Full Company Profile

Financial Performance

In 2020, MTEM's revenue was $18.85 million, a decrease of -15.38% compared to the previous year's $22.27 million. Losses were -$104.92 million, 51.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for MTEM stock is "Strong Buy." The 12-month stock price forecast is 15.38, which is an increase of 78.22% from the latest price.

Price Target
$15.38
(78.22% upside)
Analyst Consensus: Strong Buy